Results 71 to 80 of about 356,021 (162)

BAFF and APRIL Receptors in B Cell Immunity and Autoimmunity

Immunological Reviews, Volume 342, Issue 1, September 2026.
ABSTRACT BAFF and APRIL are TNF superfamily proteins that bind to BAFFR, TACI and BCMA, members of the TNF receptor superfamily. These proteins have both unique and overlapping roles in B cell development and survival and are major therapeutic targets for antibody‐ and B‐cell‐driven pathologies.
Daisy H. Luff, Edina Schweighoffer, Victor L. J. Tybulewicz   +2 more
wiley   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Forsythiaside A Alleviates Kidney Injury and Intestinal Epithelium Dysfunction in IgA Nephropathy by Inhibiting TLR4/NF‐κB Signaling

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 6, June 2026.
ABSTRACT IgA nephropathy (IgAN), the most common form of glomerulonephritis, is a major and growing public health issue. It results from intestinal barrier dysfunction that leads to mesangial deposition of pathogenic galactose‐deficient IgA1 (Gd‐IgA1) and renal inflammation.
Meng‐Si Li, Kai Liu
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Origin of poorly galactosylated IgA1 other than mucosa: a viewpoint from a report on patient with IgA vasculitis

Renal Failure
Patients presenting monoclonal gammopathy of renal significance (MGRS) and IgA vasculitis collectively have rarely been reported. This study reports one patient with monoclonal IgA and λ, and with IgA positive-mesangial proliferative glomerulonephritis ...
Manxia Huang, Jian Cao, Yangpu Li, Hua Xu, Manliu Wang, Yihou Zheng, Mumin Shao, Youjia Zeng, Jicheng Lv   +8 more
doaj   +1 more source

A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. [PDF]

PLoS ONE, 2014
There is increasing evidence that galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1-containing immune complexes are important for the pathogenesis of IgA nephropathy (IgAN).
Hiroyuki Yanagawa, Hitoshi Suzuki, Yusuke Suzuki, Krzysztof Kiryluk, Ali G Gharavi, Kiyoshi Matsuoka, Yuko Makita, Bruce A Julian, Jan Novak, Yasuhiko Tomino   +9 more
doaj   +1 more source

B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts

Immunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) is increasingly recognized not just as a lipid‐driven disease, but as a complex interplay between vascular cells and the immune system. Accumulating evidence highlights a central, yet heterogeneous role for B cells in atherogenesis, with distinct subsets displaying opposing roles.
Sophieke Lems, Megan Grace Mazzei, Amanda C. Foks, Coleen A. McNamara   +3 more
wiley   +1 more source

Telitacicept Combined With Glucocorticoids as Initial Therapy for Moderate IgA Vasculitis Nephritis With Concurrent Pulmonary Infection in Children: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
This graphical abstract depicts the clinical course of a 14‐year‐old male with moderate IgAV‐N treated with telitacicept combined with glucocorticoids as initial therapy. Rapid glucocorticoid tapering, normalized renal function, and continuous remission of proteinuria and hematuria were achieved.
Jiayi Li, Zhao Chen, Jiamei Lu, Pei Zhang, Xiaotao Ma, Xia Yang, Akhmedova Nilufar Sharipovna, Rongguo Fu   +7 more
wiley   +1 more source

A Case Study and Review of the Literature on IgA Nephropathy in Crohn's Disease

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT IgA nephropathy (IgAN) is the most frequently reported glomerular disease associated with inflammatory bowel disease (IBD), particularly Crohn's disease (CD), although pediatric cases remain rare. We report IgAN in a 16‐year‐old male with CD following intestinal surgery and during long‐term infliximab therapy, with renal impairment occurring ...
Giovanna Fernanda Vazzana, Alessia Romano, Chiara Casuscelli, Alberto La Spada, Domenico Santoro, Roberto Chimenz, Claudio Romano   +6 more
wiley   +1 more source

Unveiling the immune landscape and microenvironmental architecture of IgA nephropathy using single‐cell imaging mass cytometry

Clinical &Translational Immunology, Volume 15, Issue 3, 2026.
In IgA nephropathy (IgAN), innate and adaptive immune cells display distinct spatial compartmentalisation, with macrophages predominating within glomeruli and CD4+ T cells constituting the major immune population in inflammatory foci. Glomeruli with distinct pathological morphologies exhibit morphology‐dependent immune infiltration patterns and ...
Xing Chen, Long Liu, Lijing Yao, Jianxin Shen, Hengyuan Zhang, Leping Shao, Xingxing Yu, Zhijuan Lin, Lu Zhang   +8 more
wiley   +1 more source